Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1970 2
1971 7
1972 4
1973 1
1974 1
1976 1
1977 1
1978 2
1979 2
1980 2
1981 3
1982 4
1983 4
1984 2
1985 2
1986 4
1987 1
1988 5
1989 4
1990 6
1991 6
1992 3
1993 5
1994 2
1995 1
1996 2
1997 2
1998 1
2002 1
2003 1
2004 1
2005 1
2007 1
2008 3
2009 4
2011 4
2012 3
2013 1
2014 1
2015 1
2016 4
2017 4
2018 3
2019 2
2020 4
2021 4
2022 3
2023 2
2024 2
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Results by year

Filters applied: . Clear all
Page 1
Trial of Prasinezumab in Early-Stage Parkinson's Disease.
Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, Mollenhauer B, López-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D'Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga Š, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. N Engl J Med. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867. N Engl J Med. 2022. PMID: 35921451 Clinical Trial.
Sensing data and methodology from the Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) clinical trial.
Stanslaski S, Summers RLS, Tonder L, Tan Y, Case M, Raike RS, Morelli N, Herrington TM, Beudel M, Ostrem JL, Little S, Almeida L, Ramirez-Zamora A, Fasano A, Hassell T, Mitchell KT, Moro E, Gostkowski M, Sarangmat N, Bronte-Stewart H; ADAPT-PD Investigators. Stanslaski S, et al. Among authors: hassell t. NPJ Parkinsons Dis. 2024 Sep 17;10(1):174. doi: 10.1038/s41531-024-00772-5. NPJ Parkinsons Dis. 2024. PMID: 39289373 Free PMC article.
Long-Term Personalized Adaptive Deep Brain Stimulation in Parkinson Disease: A Nonrandomized Clinical Trial.
Bronte-Stewart HM, Beudel M, Ostrem JL, Little S, Almeida L, Ramirez-Zamora A, Fasano A, Hassell T, Mitchell KT, Moro E, Gostkowski M, Chattree G, de Bie RMA, de Neeling M, Piña-Fuentes D, Swinnen B, Starr PA, Hammer LH, Foote KD, Richardson RM, Flaherty A, Boogers A, Sa'di Q, Meoni S, Castrioto A, Stanslaski S, Summers RLS, Tonder L, Tan Y, Berrier H, Goble TJ, Raike RS, Herrington TM; ADAPT-PD Investigators. Bronte-Stewart HM, et al. Among authors: hassell t. JAMA Neurol. 2025 Nov 1;82(11):1171-1180. doi: 10.1001/jamaneurol.2025.2781. JAMA Neurol. 2025. PMID: 40982287 Free PMC article. Clinical Trial.
Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.
Taylor KI, Lipsmeier F, Scelsi MA, Volkova-Volkmar E, Rukina D, Popp W, Lambrecht S, Anzures-Cabrera J, Summers D, Abt M, Monnet A, Kilchenmann T, Schjodt-Eriksen J, Essioux L, Kustermann T, Zago W, Svoboda H, Nikolcheva T, Postuma RB, Pagano G, Lindemann M; PASADENA Investigators; Prasinezumab Study Group. Taylor KI, et al. NPJ Digit Med. 2025 Jun 16;8(1):365. doi: 10.1038/s41746-025-01572-8. NPJ Digit Med. 2025. PMID: 40523921 Free PMC article.
Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.
Pagano G, Trundell D, Simuni T, Pavese N, Marek K, Postuma RB, Shariati N, Monnet A, Moore E, Davies EW, Svoboda H, Pross N, Bonni A, Nikolcheva T; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. NPJ Parkinsons Dis. 2025 Jul 1;11(1):193. doi: 10.1038/s41531-025-01041-9. NPJ Parkinsons Dis. 2025. PMID: 40593721 Free PMC article.
Tissues and cells of the periodontium.
Hassell TM. Hassell TM. Periodontol 2000. 1993 Oct;3:9-38. doi: 10.1111/j.1600-0757.1993.tb00230.x. Periodontol 2000. 1993. PMID: 9673156 Review. No abstract available.
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Front Neurol. 2021 Oct 1;12:705407. doi: 10.3389/fneur.2021.705407. eCollection 2021. Front Neurol. 2021. PMID: 34659081 Free PMC article.
Chronic Disease Challenges in the Caribbean.
Hassell T, Hennis A. Hassell T, et al. Glob Heart. 2016 Dec;11(4):437-438. doi: 10.1016/j.gheart.2016.10.019. Glob Heart. 2016. PMID: 27938834 Free article. No abstract available.
131 results